linjc16/ctgov huggingface dataset:
Urodynamics of Suprasacral Spinal Cord Injury Patients

Study Overview
=================
Brief Summary
-----------------
The medical records of 215 patients with spinal cord injury(SCI) at the Department of Rehabilitation Medicine of the 2nd Affiliated Hospital of Wenzhou Medical University, Wenzhou, China were evaluated between January 1, 2016 and December 20, 2019. According to the inclusion criteria and exclusion criteria, 101 patients were included. The patients were dichotomized into two groups: complete SCI group and incomplete SCI group, based on the American Spinal Injury Association Guidelines Impairment Scale (AIS) .The investigators retrospectively collected records of urodynamic evaluations of this patients and then analyze the urodynamic parameters,including detrusor overactivity (DO), bladder compliance (BC), bladder-filling sensation, maximum cystometric capacity (MCC), detrusor external sphincter dyssynergia (DESD), maximum urinary flow rate (Qmax), detrusor pressure at a maximum urinary flow rate(PdetQmax).

Official Title
-----------------
Urodynamic Findings in Patients With Complete and Incomplete Suprasacral Spinal Cord Injury at Different Stages After Injury

Conditions
-----------------
Spinal Cord Injuries

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria were: the period of the spinal shock has passed. patients diagnosed with traumatic suprasacral SCI, based on AIS. urodynamic investigations were performed by the same urologist. patients with voiding dysfunction. Exclusion Criteria: The patient with voiding dysfunction before the injury were excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| detrusor overactivity (DO) | detrusor overactivity in milliliter,one of the urodynamic parameters | 0-365 days after injury | 
| bladder compliance (BC) | bladder compliance in ml/cmH2O,one of the urodynamic parameters | 0-365 days after injury | 
| bladder-filling sensation | bladder-filling sensation,one of the urodynamic parameters | 0-365 days after injury | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| maximum cystometric capacity (MCC) | maximum cystometric capacity in milliliter,one of the urodynamic parameters | 0-365 days after injury | 
| detrusor external sphincter dyssynergia (DESD) | detrusor external sphincter dyssynergia,one of the urodynamic parameters | 0-365 days after injury |
Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Study Overview
=================
Brief Summary
-----------------
Sage tablets ( 3400 mg extract from fresh sage leaves, DER 1:17) in a once daily application over 12 treatment weeks are compared against placebo in 200 menopausal patients with ≥ 5 hot flushes daily and a Hyperhidrosis Scale score ≥ 2

Official Title
-----------------
Multicentric, Randomized, Double Blind Study for Assessment of Efficacy and Tolerability of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating

Conditions
-----------------
Menopausal Hot Flushes

Intervention / Treatment
-----------------
* Drug: Sage extract, 3400 mg , DER 1:17


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Menopausal since ≥ 1 year ≥ 5 hot flushes /24 hours Hyperhidrosis Scale score ≥ 2 Exclusion Criteria: Affections like asthma, COPD, depression, diabetes, epilepsy, hyper- and hypothyreosis, malign tumours

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Sage tablets<br>Sage extract, 3400 mg , DER 1:17, in once daily application over 12 weeks treatment phase | Drug: Sage extract, 3400 mg , DER 1:17<br> <br> |
| Placebo Comparator: Placebo<br>Placebo, matching the verum in size and appearance, in once daily application over 12 weeks treatment phase | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Hyperhidrosis Disease Severity Scale |  | Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline Menopause Rating Scale / MRS |  | Week 12 | 
| Change from Baseline Modified Dem Tect |  | Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
menopause, hot flushes, hot flashes, salvia, sage, sweating
Gestational Diabetes Mellitus and Cardiometabolic Syndrome in Offspring

Study Overview
=================
Brief Summary
-----------------
Gestational Diabetes Mellitus (GDM) has long been known as leading to macrosomias, neonatal hypoglycemias and other complications which are treatable and preventable. Nowadays, GDM is recognized as an entity with long-term serious sequels to the mother (GDM is considered a forerunner of type 2 diabetes) and her offspring. Indeed, according to the programming hypothesis, GDM sets the stage for metabolic syndrome, obesity, type 2 diabetes and hypertension. However, these cross-sectional studies failed to control for maternal disease history and genetic background although heredity is a major epidemiology risk factor of type 2 diabetes. Also, studies usually refer to traditional markers such as BMI, blood pressure, lipids profile and oral glucose tolerance test (OGTT); none explored inflammatory biomarkers and adipokines in-depth, despite the possible link between their presence and the development of metabolic and cardiovascular diseases in GDM offsprings. Exclusion of genetic confounding factors will help establish the role of GDM as an independent marker of cardiometabolic risk in GDM offspring. It is highly relevant to identify GDM as a risk factor for cardiometabolic diseases, given the worldwide obesity epidemic, the alarming prevalence increase of GDM and its serious sequels to both mother and offspring.

Official Title
-----------------
Is Gestational Diabetes Mellitus (GDM) an Independent Risk Factor for Cardiometabolic Syndrome in Offspring?

Conditions
-----------------
Gestational Diabetes Mellitus

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 4 to 12 years Tanner stage < 2 to understand French or English Exclusion Criteria: Type 1 diabetes weight < 10 kg placenta abnormalities gestational age < 34 weeks illness affecting growth and metabolism taking medications

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| GDM offspring<br>Children born from gestational diabetes mellitus pregnancy | |
| No-GDM offspring<br>Children born from a normal pregnancy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Metabolic syndrome | Prevalence of metabolic syndrome | 4 to 12 years after birth. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory markers | 4 to 12 years after birth. | Assessed only once 4 to 12 years after birth |
To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia

Study Overview
=================
Brief Summary
-----------------
To Evaluate the efficacy of Z-338 in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms in order to further determine the optimal dosage and efficacy parameters for PhaseIII clinical trials.

Official Title
-----------------
To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia, Focusing on the Assessment of Subjective Symptoms

Conditions
-----------------
Functional Dyspepsia

Intervention / Treatment
-----------------
* Drug: Z-338


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Postprandial fullness, upper abdominal bloating and/or early satiety should be at least moderate for 2 days or more at the 7 days at Visit 1 upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiety, nausea, vomit and belching should be at least moderate for at least 2 symptoms for 2 days or more at the 7 days at Visit 1 Exclusion Criteria: subjects taht heartburn should be the most bothersome symptom Subjects presenting with primary complaints relieved by stool movements (IBS) Subjects with diabetes by treatment Subjects taht heartburn should be more than moderate

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Z-338|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| General impression at last visit |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| General impression at each week |  |  | 
| Individual symptom score |  |  |
Proton Therapy Medical Registry

Study Overview
=================
Brief Summary
-----------------
Clínica Universidad de Navarra Proton Therapy Unit is establishing a registry to capture the full radiation dosimetry delivered to the patient, baseline clinical data, and disease, toxicity and quality of life outcomes. The objectives are parameters prescribed and to have all patients treated at the proton therapy unit to be included in the registry to enable future analysis of treatment outcomes to assist in understanding, which patients can benefit from the use of protons.

Detailed Description
-----------------
Proton based radiation therapy has considerable dosimetric advantages over the standard photon based external beam radiation therapy, with an increased cost. Now, the clinical advantages, however, may not be identified in general, even with the improved dose distributions. In a large-scale evaluation, in time of personalized/ precision medicine, the impact of dosimetric benefit int clinical benefit meds registration studies.

Official Title
-----------------
Proton Therapy Medical Registry

Conditions
-----------------
Cancer, Therapy-Related

Intervention / Treatment
-----------------
* Radiation: Other: Registry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients treated at the proton center Exclusion Criteria: Any other than what is supplied in the inclusion criteria
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cancer patients receiving proton radiation therapy<br>Cancer patients receiving proton radiation therapy, Registry of cancer patients who receive proton radiation therapy to crack disease and toxicity outcomes. | Radiation: Other: Registry<br>* Registry of cancer patients who receive proton radiation therapy.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome Mesure | Clinical outcomes will be obtains from electronic chart including: images, blood test, pathology and clinical reports | 20 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proton therapy Additional relevant MeSH terms: Neoplasms, Secondary Primary Neoplasms, Cancer
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

Study Overview
=================
Brief Summary
-----------------
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.

Detailed Description
-----------------
PRIMARY OBJECTIVES: I. To identify, using next generation sequencing, rare variants of large effect size that impact the risk of hypertension in patients from the clinical trial Eastern Cooperative Oncology Group (ECOG)-5103 (E5103). OUTLINE: Previously collected germline DNA samples are analyzed via whole exome sequencing.

Official Title
-----------------
Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples

Conditions
-----------------
Breast Carcinoma

Intervention / Treatment
-----------------
* Other: Laboratory Biomarker Analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: European American patients with deoxyribonucleic acid (DNA) available and designated case or control Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab Patients who did not develop hypertension following a full course of treatment with bevacizumab
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ancillary-Correlative (whole exome sequencing)<br>Previously collected germline DNA samples are analyzed via whole exome sequencing. | Other: Laboratory Biomarker Analysis<br>* Correlative studies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of rare coding variants of large effect that predict the risk of bevacizumab-induced hypertension | Burden analysis will be used. | Baseline |
DPBRN Blood Sugar Testing in Dental Patients

Study Overview
=================
Brief Summary
-----------------
The principal goal of this study was to assess the feasibility of plasma glucose testing in private dental practice. A second aim was was to assess prevalence of plasma glucose abnormalities in dental patients seen by (DPBRN) practitioner-investigators.

Detailed Description
-----------------
The specific aims of this study were: To quantify the percentage of (DPBRN) patients who meet the American Diabetes Association screening criteria and to describe the characteristics of these patients. To quantify the acceptability of conducting glucose testing in the dental office and barriers to regular screening, as reported by (DPBRN) patients and practices.

Official Title
-----------------
Blood Sugar Testing in Dental Patients

Conditions
-----------------
Diabetes Mellitus, Hyperglycemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults over the age of 19 who were scheduled for a visit with an exam Exclusion Criteria: patients undergoing continuing treatment where an exam was not part of the visit were not eligible

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Glucose testing<br>Patients participating in this study may be alerted to possible presence of (DM) or pre-(DM) or to inadequate glycemic control. In such a case, they were advised to follow-up with their physician for definitive diagnosis and treatment. Early diagnosis and improved glycemic control may be of significant benefit to the patients' health. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
glucose testing
Dental PROBE (Dental Practice suRvey of Office Blood Pressure mEasurement)

Study Overview
=================
Brief Summary
-----------------
20% of Canadians are hypertensive with approximately 200,000 new cases each year. Early detection of hypertension affects outcomes, reducing the risk for heart attack, stroke, kidney disease, and dementia. Screening strategies are required to identify the more than one third of Canadians with unrolled high blood pressure, in particular, younger men unaware of their condition, women over sixty years old, and underserved groups. A collaborative practice model linking dentists to other healthcare providers in a reporting network is a promising model for hypertension detection and management. There are 20,129 licensed dentists in Canada who graduate with the ability to measure blood pressure, and 74% of the population visits a dentist each year. This represents an opportunity, but information is required on Dental attitudes toward screening for hypertension before attempting to initiate a screening model. To engage dentists in hypertension detection requires an understanding of the practice environment and the factors that shape their beliefs, attitudes and behaviours regarding routine hypertension screening in their practices.

Official Title
-----------------
A Mixed Methods Study to Assess How to Engage Dentists in Blood Pressure Screening

Conditions
-----------------
Focus of Study is on Dentist's Attitudes Toward BP Measures

Intervention / Treatment
-----------------
* Behavioral: focus group


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dentists in practice Exclusion Criteria: Unwilling to participate in study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dentists<br>Dentists in practice | Behavioral: focus group<br>* key informant review<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, dentistry, blood pressure, measurement, screening, qualitative research
Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair

Study Overview
=================
Brief Summary
-----------------
Umbilical and epigastric hernia repairs are common and performed by numerous surgical techniques. Considering that the hernia repairs in general are relatively small and simple procedures there are disproportionate poor results. The aim of present study is to determine surgical risk factors for readmission after umbilical and epigastric hernia repair and to report risk factors for later reoperation for recurrence.

Detailed Description
-----------------
All elective umbilical or epigastric hernias registered in the Danish Ventral Hernia Database are included in the study. The included patients will be followed in up to 4 years in order to identify correlation between technical aspects of the hernia repair and postoperative morbidity.

Official Title
-----------------
Nationwide Prospective Study of Surgical Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair

Conditions
-----------------
Umbilical Hernia, Epigastric Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Umbilical or epigastric hernia repair Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 120 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Danish Ventral Hernia Database<br>Patients registered in the Danish Ventral Hernia Database during January 1st 2007 to december 31st 2010 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| readmission | Riskfactors for readmission within 30 days after umbilical or epigastric hernia repair | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| reoperation for recurrence | Risk factors for recurrence repair after umbilical or epigastric hernia repair | up to 4 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
readmission, recurrence, umbilical, epigastric, hernia, outcome, morbidity